Role of ivermectin in the prevention of SARS- CoV-2

PLOS ONE

a1111111111 a1111111111 a1111111111 a1111111111 a1111111111

OPEN ACCESS

Citation: Behera P, Patro BK, Singh AK, Chandanshive PD, S. R. R, Pradhan SK, et al. (2021) Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study. PLoS ONE 16(2): e0247163. https://doi.org/10.1371/journal. pone.0247163

Editor: Muhammad Adrish, BronxCare Health System, UNITED STATES

Received: December 14, 2020 Accepted: February 2, 2021 Published: February 16, 2021

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: https://doi.org/10.1371/journal.pone.0247163

Copyright: © 2021 Behera et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: The anonymized data set has been uploaded to the public repository (figshare). The dataset can be accessed at the

RESEARCH ARTICLE

Role of ivermectin in the prevention of SARS- CoV-2 infection among healthcare workers in India: A matched case-control study

Priyamadhaba Behera1, Binod Kumar Patro1, Arvind Kumar Singh1, Pradnya
Dilip Chandanshive1, Ravikumar S. R.ID1, Somen Kumar Pradhan1, Siva Santosh Kumar Pentapati1, Gitanjali BatmanabaneID2*, Prasanta Raghab Mohapatra3, Biswa Mohan Padhy4, Shakti Kumar Bal3, Sudipta Ranjan Singh5, Rashmi Ranjan Mohanty6

1 Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India, 2 All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India, 3 Department of Pulmonary Medicine and Critical Care, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India, 4 Department of Pharmacology, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India, 5 Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India, 6 Department of General Medicine, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India

* director@aiimsbhubaneswar.edu.in

Abstract

Background

Ivermectin is one among several potential drugs explored for its therapeutic and preventive role in SARS-CoV-2 infection. The study was aimed to explore the association between iver- mectin prophylaxis and the development of SARS-CoV-2 infection among healthcare workers.

Methods

A hospital-based matched case-control study was conducted among healthcare workers of AIIMS Bhubaneswar, India, from September to October 2020. Profession, gender, age and date of diagnosis were matched for 186 case-control pairs. Cases and controls were health- care workers who tested positive and negative, respectively, for COVID-19 by RT-PCR. Exposure was defined as the intake of ivermectin and/or hydroxychloroquine and/or vita- min-C and/or other prophylaxis for COVID-19. Data collection and entry was done in Epicol- lect5, and analysis was performed using STATA version 13. Conditional logistic regression models were used to describe the associated factors for SARS-CoV-2 infection.

Results

Ivermectin prophylaxis was taken by 76 controls and 41 cases. Two-dose ivermectin pro- phylaxis (AOR 0.27, 95% CI, 0.15–0.51) was associated with a 73% reduction of SARS- CoV-2 infection among healthcare workers for the following month. Those involved in physi- cal activity (AOR 3.06 95% CI, 1.18–7.93) for more than an hour/day were more likely to contract SARS-CoV-2 infection. Type of household, COVID duty, single-dose ivermectin

PLOS ONE | https://doi.org/10.1371/journal.pone.0247163 February 16, 2021 1 / 12

PLOS ONE

Role of oral ivermectin chemoprophylaxis in control of SARS-CoV-2 infection

following link: https://doi.org/10.6084/m9.figshare. 13603454.

Funding: The author(s) have received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

prophylaxis, vitamin-C prophylaxis and hydroxychloroquine prophylaxis were not associated with SARS-CoV-2 infection.

Conclusion

Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was associ- ated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the fol- lowing month. Chemoprophylaxis has relevance in the containment of pandemic.

Introduction

The SARS-CoV-2pandemic has claimed over 2,041,426 lives and affected over 95,567,167 per- sons worldwide by 18th January 2021 [1]. Meanwhile, the subcontinent of India has reported 10,572,672 active coronavirus disease 2019 (COVID-19) confirmed cases and 152,458 deaths related to the same virus [2]. The respiratory system is commonly involved in COVID-19, causing fever, cough and dyspnoea [3]. Alteration of the smell and taste, gastrointestinal symp- toms, headache, and cutaneous manifestations are other associated symptoms that have been reported with COVID-19 [4–7].

Worldwide, healthcare workers (HCW) working on the frontline are at risk of exposure to the virus as they battle to save patients with COVID-19. A systematic review on infection and deaths in HCWs due to COVID-19 found that the number of infected HCWs workers ranged from 1,716 to 17,306, varying from country to country [8]. Another report in September 2020 stated that COVID-19 had infected nearly 570,000 HCWs while as many as 2,500 had suc- cumbed to the disease in the region of the Americas [9]. Organizations at international and national levels have shared advisories and guidelines with measures to ensure the safety of HCWs while they serve amidst the COVID-19 pandemic. Provision of Personal Protective Equipment (PPE) while on duty, free-of-cost SARS-CoV-2 testing, timely payments, support helplines, online discussions, training, and capacity building for infection prevention and con- trol are some of the measures taken to prevent the infection and spread of COVID-19 among HCWs [10–12].

For high-risk persons such as HCWs, additional safety measures are deemed necessary to prevent them from getting infected. During initial part of the pandemic, hydroxychloroquine (HCQ) as a chemoprophylaxis agent was used in India under the recommendation of a few experts with little evidence and lack of scientific data [13, 14]. The World Health Organiza- tion’s(WHO) Solidarity trial’s Executive Group and principal investigators decided to stop the hydroxychloroquine arm based on evidence from the Solidarity trial and UK’s Recovery trial, which showed that HCQ did not result in the reduction of mortality of hospitalized COVID- 19 patients compared with standard of care [15]. Ivermectin has been used as a therapeutic treatment of mild to moderate COVID-19 cases [16]. It has also been found to prevent symp- toms of COVID-19 in post-exposure prophylaxis among HCWs [17]. A clinical trial con- ducted in Egypt in high-risk contacts of COVID-19 patients reported that compared to 7.4% of participants in the ivermectin arm, 58.5% in the control arm had symptoms suggesting SARS-CoV-2 infection [17]. A Few other studies have also shown favorable results with the use of ivermectin as prophylaxis and treatment [18, 19].

All India Institute of Medical Sciences, Bhubaneswar, is a tertiary care, government-funded teaching hospital situated in Odisha, in the Eastern part of India. From August 2020 onwards, a large number of HCWs employed in the hospital got infected, thus affecting hospital services.

PLOS ONE | https://doi.org/10.1371/journal.pone.0247163 February 16, 2021 2 / 12

PLOS ONE

Role of oral ivermectin chemoprophylaxis in control of SARS-CoV-2 infection

Ivermectin has been shown to have diverse mechanisms by which it targets SARS-CoV-2and has a proven safety profile of many decades. These facts, along with the encouraging results of the study from Egypt, prompted us to explore the role of ivermectin as a prophylactic agent against COVID-19 in HCWs.

Materials and methods

Study population and sample size

The present study is a hospital-based matched case-control study conducted among HCWs of the All India Institute of Medical Sciences (AIIMS) in Bhubaneswar, Odisha, India, during September-October 2020. To calculate sample size, we assumed ivermectin prophylaxis in the control group to be 22% as there were no data available from prior studies. Considering, 80% power, 5% alpha, 1:1 matching of cases to controls, minimum discordant pairs to be detected was set to 54, with an expected odds ratio of 0.5, the sample size was estimated to be 186 pairs, i.e., 372 individuals [20]. Cases and controls were identified from the existing line list, which was prepared by the contact tracing team at AIIMS Bhubaneswar. The line list contained the list of the AIIMS Bhubaneswar HCWs’ risk of exposure to SARS-CoV-2based on the assess- ment carried out using the WHO risk assessment guidelines [21]. This risk assessment helped in identifying population of cases and controls having similar risk. Cases were HCWs who were diagnosed as positive for COVID-19 by Reverse Transcription Polymerase Chain Reac- tion (RT-PCR). Controls were defined as HCWs who were diagnosed as negative for COVID- 19 by RT-PCR with a similar risk of exposure toSARS-CoV-2. For every enrolled case, a con- trol was selected from the existing line list. Individual matching was carried out for profession, gender and age. In addition, an attempt was made to match the date of diagnosis. However, when the match was not possible for the same date, the control was selected from the nearest possible date of diagnosis. In the majority of cases, it was within a week. The average number of days for a difference in date of diagnosis was 3.8 days between cases and controls. Exposure was defined as the prophylaxis viz., ivermectin and/or (HCQ) and/or vitamin C and/or other agent taken for the prevention of COVID-19. The HCWs of AIIMS Bhubaneswar were advised to take HCQ prophylaxis as per Indian Council of Medical Research (ICMR) guidelines from 11thApril 2020 [22], in addition to using appropriate PPE depending on the place they were posted. However, the uptake was not encouraging on account of known cardiovascular adverse effects of HCQ. Further, on 17thSeptember 2020, a decision to provide all HCWs with ivermec- tin for prophylactic use was announced, based on a consensus statement that was released at the institute (Box 1).

Data collection and statistical analysis

The cases and controls dates range from 20th September 2020 to 19th October 2020. Partici- pants were contacted for interviews from 19th October 2020 to 24th October 2020. After the selection of cases and controls, a phone call was made to each participant. The data related to COVID duty, family type, history of prophylaxis intake, history of hospital admission and physical activity were collected. (S1 Appendix) Data was entered in Epicollect5. Data cleaning and analysis was done using STATA version 13. The difference in characteristics of cases and controls were assessed using the chi-square test for categorical variables and t-test for continu- ous variables. Mean and standard deviation was used for continuous variables and proportion for categorical variables. Matched pair analysis was done using the McNemar chi-square test. Matched pair odds ratio was estimated for ivermectin, vitamin-C and HCQ prophylaxis. The potential confounders which could not be matched were adjusted during analysis with condi- tional logistic regression models. In model 1, we included the variables -COVID duty, family

PLOS ONE | https://doi.org/10.1371/journal.pone.0247163 February 16, 2021 3 / 12

PLOS ONE

Role of oral ivermectin chemoprophylaxis in control of SARS-CoV-2 infection

Box 1. AIIMS Bhubaneswar consensus statement for ivermectin prophylaxis among healthcare workers

Based on the long history of clinical use, favourable safety profile, and the reportedly promising effect of ivermectin as a prophylactic agent in COVID-19, the expert commit- tee group proposes the following consensus statement:

Suggested prophylaxis for doctors/nurses/staff/students of AIIMS Bhubaneswar with ivermectin�

First Dose:

Ivermectin 300 μg/kg body weight on Day 1 (Directly Observed) and 4 (72 hours apart).

For 40–60 kg:15mg, 60–80 kg:18 mg, > 80 kg:24 mg

Subsequent dose: once a month dose (as above/kg body weight) on every 30th day after the last dose.

Ivermectin should be taken on an empty stomach with water.
�The above schedule will be followed till further guideline/new evidence is available.

�Pregnant women will not be given this drug. Women of childbearing age will be warned not to conceive while on this drug, in case they decide to take the drug.

This consensus statement had been prepared by a team of faculty members from various specialities and discussed and approved in the COVID-19 Working Group meeting on 11th September 2020.

type and physical activity (a proxy for social contacts), which may be the risk factors for COVID-19. In model 2, we included the variables- ivermectin, vitamin-C and HCQ, which were practiced as prophylaxis by HCWs for the prevention of COVID-19.

The study protocol was approved by the Institutional Ethics Committee of AIIMS, Bhuba- neswar, via ref number: T/IM-NF/CM&FM/20/125. (S1 Protocol) Verbal informed consent was obtained telephonically before participation in the study. This consent procedure was approved by the ethics committee.

Results

A total of 904 individuals working in AIIMS, Bhubaneswar, got tested for SARS-CoV-2 during one month (20th September 2020-19th October 2020). Out of 904 persons who were tested, 234 persons tested positive, and 670 persons tested negative for COVID-19. After matching with the profession, gender, age and date of diagnosis, there were 190 cases for which controls were available. Out of 190 cases, four did not give consent for participation. Therefore,186 matched pairs or 372 participants were finally included in our study. Participants had a mean (SD) age of 29± 6.83 years, and the mean difference in date of diagnosis between cases and control was 3.8 days. In one matched case-control pair, one intern was matched with a final year under- graduate student, which was the closest possible match for the case. The profession of the remaining 185 case-control pairs was perfectly matched (Table 1). Out of 186 cases, 18 (9.7%) cases were admitted to a hospital, while 168 (91.3%) cases opted for home isolation.

PLOS ONE | https://doi.org/10.1371/journal.pone.0247163 February 16, 2021 4 / 12

PLOS ONE

Role of oral ivermectin chemoprophylaxis in control of SARS-CoV-2 infection

Table 1. Characteristics of study participants(n = 372).

Mean age in years (Mean ± SD) Age groups
<30 years
30–39 years

P-value

Control (n = 186)

Case (n = 186)

Total (n = 372)

29.26 ± 6.61

29.25 ± 7.05

29.25 ± 6.83

0.99 0.73

110 (59.1%)

116 (62.4%)

226 (60.8%)

59 (31.7%)

52 (28.0%)

111 (29.8%)

15 (8.1%)

14 (7.5%)

29 (7.8%)

2 (1.1%)

4 (2.1%)

6 (1.6%)

40–49 years
�50 years
Gender
Male 1.00 Female

Whether you had COVID-19 dutya in the hospital?
Yes 0.92 No
Daily duration of physical activity
No physical activity
Less than 30 minutes
30–59 minutes
�60 minutes
Profession
Support staff
Residents
Nursing Officer
Intern
Student
Faculty
Type of household
Extended family
Nuclear family
With friend or roommate
Living alone
Total

125 (67.2%)

250 (67.2%)

61 (32.8%)

122 (32.8%)

107 (57.5%)

106 (57.0%)

213 (57.3%)

79 (42.5%)

80 (43.0%)

159 (42.7%)

159 (85.5%)

147 (79.0%)

306 (82.3%)

6 (3.2%)

8 (4.3%)

14 (3.7%)

14 (7.5%)

11 (5.9%)

25 (6.7%)

7 (3.8%)

20 (10.8%)

27 (7.3%)

0.06

1.00

0.26

52 (28.0%)

104 (28.0%)

36 (19.3%)

36 (19.4%)

72 (19.4%)

64 (34.4%)

128 (34.4%)

12 (6.5%)

13 (7.0%)

25 (6.7%)

13 (7.0%)

12 (6.4%)

25 (6.7%)

9 (4.8%)

18 (4.8%)

86 (46.2%)

98 (52.7%)

183 (49.5%)

28 (15.1%)

20 (10.7%)

48 (12.9%)

64 (34.4%)

55 (29.6%)

119 (32.0%)

8 (4.3%)

13 (7.0%)

21 (5.6%)

186 (100.0%)

372 (100.0%)

aCOVID-19 duty was defined as HCWs involved in COVID-19 patient care in the outpatient department (OPDs) and/or inpatient department (IPDs) and/or intensive care unit (ICU).

https://doi.org/10.1371/journal.pone.0247163.t001

The majority of the participants (60.75%) were below 30 years of age. Nearly two-thirds of participants (67.2%) were male. More than half of the participants (57.26%) were involved in COVID-19 patient care in the outpatient department (OPDs) and/or inpatient department (IPDs) and/or intensive care unit (ICU) in the last one month. Most participants (82.26%) were not doing any physical activity during the study period. Among the various modes of physical activity, jogging and yoga were chosen by 38 participants each (10.22%), gymnasium by 15 (4.03%), and sports by 11 (2.96%) participants. Among 372 participants, 128 (34.41%) were nursing officers, 104 (27.96%) were supporting staffs, 72 (19.35%) were resident doctors, 25 (6.72%) were interns, 25 (6.72%) were students and 18 (4.84%) were faculty members. Half of the participants (49.33%) were staying in an extended family, one-third of participants (32.08%) were staying with friends, and others were either staying in a nuclear family (12.94%) or living alone (5.66%) (Table 1).

PLOS ONE | https://doi.org/10.1371/journal.pone.0247163 February 16, 2021 5 / 12

PLOS ONE

Role of oral ivermectin chemoprophylaxis in control of SARS-CoV-2 infection

Out of 372 participants, 171 participants (101 from cases and 70 from controls) took any form of prophylaxis. Hundred and seventeen (31.4%) participants had a history of ivermectin prophylaxis-76 from controls and 41 from cases, 67 (18.01%) participants had a history of vita- min-C prophylaxis-38 from controls and 29 from cases, 19(5.11%) participants had a history of HCQ prophylaxis-12 from controls and seven from cases (Table 2). Four participants were taking home-based remedies for the prevention of COVID-19. Ninety-one (24.46%) partici- pants had a history of two-dose ivermectin prophylaxis (300 μg/kg at Day 1 and Day 4). How- ever, 17 (4.57%) participants took only one dose (300 μg/kg), and 9 (2.42%) participants continued the same dose for three or more days. Out of 67 participants, who took vitamin-C prophylaxis, 54 participants took a dose of 500 mg once daily, and 13 participants took vita- min-c 500 mg twice daily. The majority of participants took vitamin-C for less than one month; however, 27 participants were continuing vitamin-C prophylaxis for more than one month. HCQ prophylaxis was practiced 400 mg once a week. Out of 19 participants who took HCQ prophylaxis, ten participants took for three or more weeks, five participants took for two weeks, and four participants took for a week.

In the matched pair analysis, ivermectin prophylaxis (OR 0.35, 95% CI, 0.20–0.60) was asso- ciated with the reduction of SARS-CoV-2 infection. However, vitamin-C prophylaxis (OR 0.71, 95% CI, 0.40–1.26) and HCQ prophylaxis (OR 0.58, 95% CI, 0.19–1.61) had no signifi- cant association with SARS-CoV-2 infection (Table 3). In the multivariate conditional logistic regression model 2, two-dose of ivermectin prophylaxis (AOR 0.27, 95% CI, 0.15–0.51) was associated with a reduction of SARS-CoV-2 infection after adjusting for COVID duties, type of household, physical activity, vitamin-C prophylaxis and HCQ prophylaxis. However, physi- cal activity for more than one hour was an independent risk factor (AOR 3.06 95% CI, 1.18– 7.93) for SARS-CoV-2 infection (Table 4).

Discussion

Our study has shown that two doses of ivermectin prophylaxis at a dose of 300 μg/kg given 72 hours apart was associated with a 73% reduction of SARS-CoV-2 infection among HCWs for the following month. Our results are similar to the randomized trial conducted by Waheed Shouman from the Zagazig University of Egypt. Out of the 203HCWs in the intervention arm,

Table 2. Comparison of nature of prophylaxis between the cases (n = 186) and controls (n = 186).

Control N (%)

Case N (%)

Variable
History of any prophylaxis

No
Yes
History of intake of ivermectin for COVID-19 prophylaxis No
Yes
History of intake of vitamin-C for COVID-19 prophylaxis No
Yes
History of intake of HCQa for COVID-19 prophylaxis
No
Yes
Total

aHydroxychloroqune (HCQ).

https://doi.org/10.1371/journal.pone.0247163.t002

Total N (%)

201 (54.0) 171 (46.0)

255 (68.6) 117 (31.4)

305 (82.0) 67 (18.0)

353 (94.9) 19 (5.1) 372 (100.00)

85 (45.7)

116 (62.37)

101 (54.3)

70 (37.6)

110 (59.1)

145 (78.0)

76 (40.9)

41 (22.0)

148 (79.6)

157 (84.4)

38 (20.4)

29 (15.6)

174 (93.5)

179 (96.2)

12 (6.5)

7 (3.8)

186 (100.00)

PLOS ONE | https://doi.org/10.1371/journal.pone.0247163 February 16, 2021

6 / 12

PLOS ONE Role of oral ivermectin chemoprophylaxis in control of SARS-CoV-2 infection Table 3. Matched pair analysis of exposure/prophylaxis taken for COVID-19 (n = 186).

Variables

McNemar’s Chi-square

χ2 = 16.78 P<0.001

χ2 = 1.47 P = 0.22

χ2 = 1.32 P = 0.25

Model-2

Cases

Ivermectin

Controls

No ivermectin

19 (17.3%)

Total

Ivermectin

22 (29.0%)

41 (22.0%)

No ivermectin

54 (71.0%)

91 (82.7%)

145 (78.0%)

Total

76 (100.0%)

110 (100.0%)

186 (100.0%)

Matched pair ORa

0.35 (95% CI, 0.20 to 0.60)

Vitamin-C

No vitamin-C

Vitamin-C

6 (15.8%)

23 (15.5%)

29 (15.6%)

No vitamin-C

32 (84.2%)

125 (84.5%)

157 (84.4%)

Total

38 (100.0%)

148 (100.0%)

186 (100.0%)

Matched pair OR

0.71 (95% CI, 0.40 to 1.26)

HCQ

No HCQ

HCQb

0 (0.0%)

7 (4.0%)

7 (3.8%)

No HCQb

12 (100.0%)

167 (96.0%)

179 (96.2%)

Total

12 (100.0%)

174 (100.0%)

186 (100.0%)

Matched pair OR

0.58 (95% CI, 0.19 to 1.61)

aOddss Ratio (OR) and bHydroxychloroqune (HCQ).

https://doi.org/10.1371/journal.pone.0247163.t003

Table 4. Conditional logistic regression models for associated factors of SARS-CoV-2 infection. Variable

History of COVID-19 duty

Yes

Household type

Extended family

Friend/roommate

Nuclear family

Alone

Physical activity

No physical activity

Less than 30 minutes per day

30–59 minutes per day

�60 minutes per day

Ivermectin prophylaxis

No Ivermectin prophylaxis

Single-dose Ivermectin prophylaxis

Two or more doses Ivermectin prophylaxis

Vitamin-C prophylaxis

No
Yes
Hydroxychloroquine prophylaxis No
Yes

https://doi.org/10.1371/journal.pone.0247163.t004

p- value

0.69

0.48 0.25 0.57

0.82 0.31 0.02

0.63

0.00

0.58

0.29

Unadjusted Odds ratio (95% CI)

p-value

Model-1

Adjusted Odds ratio (95% CI)

p-value

Adjusted Odds ratio (95% CI)

Reference

0.96 (0.55 to1.66)

0.89

0.93(0.51 to 1.67)

0.81

0.88 (0.45 to 1.68)

Reference

0.68 (0.39 to 1.18)

0.18

0.69(0.39 to 1.21)

0.19

0.80 (0.43 to 1.48)

0.61(0.31 to 1.19)

0.15

0.64(0.32 to 1.27)

0.20

0.66 (0.32 to 1.35)

1.51 (0.49 to 4.66)

0.47

3.25(0.53 to 5.45)

0.37

1.43 (0.42 to 4.91)

Reference

1.33(0.46 to 3.84)

0.59

1.34 (0.46 to 3.92)

0.60

1.14 (0.36 to 3.61)

0.80(0.35 to 1.83)

0.60

0.76 (0.33 to 1.79)

0.53

0.61 (0.24 to 1.57)

2.83 (1.20 to 6.71)

0.02

2.86 (1.19 to 6.87)

0.02

3.06 (1.18 to 7.93)

Reference

1.23(0.43 to 3.50)

0.70

1.30 (0.44 to 3.85)

0.27(0.14 to 0.47)

0.00

0.27 (0.15 to 0.51)

Reference

0.72(0.42 to 1.27)

0.23

0.82 (0.45 to 1.57)

Reference

0.58(0.23 to 1.48)

0.26

0.56 (0.19 to 1.63)

PLOS ONE | https://doi.org/10.1371/journal.pone.0247163

February 16, 2021

7 / 12

PLOS ONE

Role of oral ivermectin chemoprophylaxis in control of SARS-CoV-2 infection

only 7.4% developed symptoms versus 58.5% of the 101 HCWs in the control arm after 14 days of enrolment. The study also reported no mortality or serious adverse events due to iver- mectin in the intervention arm [17]. Mostly, ivermectin prophylaxis will benefit the HCWs who are vulnerable to the infection because of their profession. Our study findings throw light in the same direction that ivermectin may play a vital role in the prevention strategy of SARS– CoV-2 infection.

Our study also documented that single-dose ivermectin prophylaxis at a dose of 300 μg/kg, HCQ prophylaxis, and vitamin-C prophylaxis are not associated with preventing SARS-CoV-2 infection. Engaging in physical activity for more than one hour daily, which is taken for lack of physical distancing, was an independent risk factor for SARS-CoV-2 infection in our study. Study participants practiced outdoor physical activity like walking or jogging, many also worked out at the gymnasium, and a few were involved in playing sports. The possible expla- nations may be that physical activity poses a greater risk of exposure to infection due to increased chances of social contact, difficulty wearing masks, and sharing of gymnasium equipment by multiple persons, thereby rendering individuals vulnerable to infection. Various studies have emphasized the need and effectiveness of social or physical distancing as a preven- tive measure against COVID-19 while maintaining the importance of hygiene measures, use of face masks, and increase in testing facilities to prevent and reduce COVID-19 transmission [23–27].

The study by Caly et al. on the effect of ivermectin acting in vitro on Vero-hsLAM cells infected with COVID-19 has been quoted widely for providing the basis of usage of Ivermectin in COVID-19 [28]. It was found that the Vero/hsLAM cells infected with SARS-CoV-2 isolate Australia/VIC01/2020 and treated with 5μM ivermectin showed a 93% reduction in the viral RNA compared to the vehicle DMSO (Dimethyl sulfoxide) at the end of 24 hours duration. As much as 5000-fold reduction of viral RNA was observed at the end of 48 hours duration in the ivermectin-treated samples compared to the control samples. This observation indicated that approximately all viral material was eradicated by ivermectin treatment in 48 hours duration. However, at 72 hour-duration, there was no further reduction observed in the viral RNA levels. The study also determined the IC50 (half maximal inhibitory concentration) of ivermectin treatment to be 2.5μM under the test conditions [28].

Our study also estimated that single-dose prophylaxis has no association with a reduction of SARS-CoV-2 infection, and two-dose of ivermectin (300 μg/kg) was associated with a reduction of SARS-CoV-2 infection. Our study finding is supported by another study con- ducted by Chang et al., which found ivermectin to be useful as prophylaxis among healthcare personnel [18]. Their study aimed to investigate specifically post-exposure prophylaxis in con- tacts who tested negative for SARS-CoV-2 with ivermectin dose of 0.2mg/kg body weight on day one with an additional second dose of ivermectin on day 2 or 3 for men aged more than 45 years [18]. In contrast, our study investigated the healthcare workers who had tested for COVID-19 with positive cases and negative controls. We also matched the cases and controls according to age, gender, designation, and date of testing. Also, our sample size was larger than the former study.

A randomized controlled study conducted by Boulware et al. tested hydroxychloroquine as postexposure prophylaxis among high-risk contacts of confirmed COVID-19 cases. Similar to our study findings, their study reported no significant difference between the HCQ arm and the placebo arm. There were also more side effects reported with hydroxychloroquine in their study [29].

In literature, the proposed hypothesis is that vitamin C may have a role in preventing SARS-CoV-2 infection due to its potent antioxidant and immunomodulatory effects [30–32].

PLOS ONE | https://doi.org/10.1371/journal.pone.0247163 February 16, 2021 8 / 12

PLOS ONE

Role of oral ivermectin chemoprophylaxis in control of SARS-CoV-2 infection

However, no research or hardcore evidence supports these findings. In our study, we did not find any association between vitamin-C prophylaxis and prevention of SARS-CoV-2 infection. The strengths of our study are the adequate sample size, completeness of the data collection and verification from subjects. All the HCWs received ivermectin procured from a single man-

ufacturer and belonged to the same batch for each strength. We adjusted for confounders by matching and multivariate analysis. Though recall bias is inherent in case-control studies, our data regarding the drug intake within the last one month is less likely to be forgotten by HCWs. Due to its observational nature, our study’s findings need further confirmation using longitudinal studies or interventional studies to strengthen the evidence before its large-scale use among HCWs and the implementation of public health programs.

Conclusion

We conclude that two-dose ivermectin prophylaxis at a dose of 300 μg/kg body weight with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among HCWs in the following one month. Chemoprophylaxis has relevance in the containment of pandemic. This is an intervention worth replicating at other centers until a vaccine is widely available.

Supporting information

S1 Appendix. Questionnaire used in the study (English and Odia language).

(PDF)

S1 Protocol. Study protocol.

(DOC)

Acknowledgments

We thank Mrs. Jyoti Muthusami for her assistance with language editing that significantly improved the manuscript. We are thankful to all the participants for their involvement in the study.

Author Contributions

Conceptualization: Priyamadhaba Behera, Binod Kumar Patro, Gitanjali Batmanabane, Pra- santa Raghab Mohapatra, Biswa Mohan Padhy, Shakti Kumar Bal, Rashmi Ranjan Mohanty.

Data curation: Pradnya Dilip Chandanshive, Ravikumar S. R., Somen Kumar Pradhan, Siva Santosh Kumar Pentapati.

Formal analysis: Priyamadhaba Behera, Pradnya Dilip Chandanshive, Ravikumar S. R. Investigation: Priyamadhaba Behera, Binod Kumar Patro, Somen Kumar Pradhan, Gitanjali

Batmanabane.

Methodology: Priyamadhaba Behera, Binod Kumar Patro, Arvind Kumar Singh, Ravikumar S. R., Somen Kumar Pradhan, Siva Santosh Kumar Pentapati, Gitanjali Batmanabane.

Project administration: Priyamadhaba Behera, Binod Kumar Patro, Arvind Kumar Singh, Gitanjali Batmanabane.

Resources: Priyamadhaba Behera, Arvind Kumar Singh, Gitanjali Batmanabane, Sudipta Ran- jan Singh.

PLOS ONE | https://doi.org/10.1371/journal.pone.0247163 February 16, 2021 9 / 12

PLOS ONE

Role of oral ivermectin chemoprophylaxis in control of SARS-CoV-2 infection

Supervision: Priyamadhaba Behera, Binod Kumar Patro, Arvind Kumar Singh, Gitanjali Batmanabane.

Writing – original draft: Priyamadhaba Behera, Pradnya Dilip Chandanshive, Gitanjali Batmanabane.

Writing – review & editing: Priyamadhaba Behera, Binod Kumar Patro, Arvind Kumar Singh, Somen Kumar Pradhan, Siva Santosh Kumar Pentapati, Gitanjali Batmanabane, Pra- santa Raghab Mohapatra, Biswa Mohan Padhy, Shakti Kumar Bal, Sudipta Ranjan Singh, Rashmi Ranjan Mohanty.

References

1. WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. The World Health Organization; c2021-
[cited 2020 Nov 6]. Available from: https://covid19.who.int.

2. Ministry of Health and Family Welfare [Internet]. Government of India; c2021- [cited 2020 Nov 6]. Avail-
able from: https://www.mohfw.gov.in/.

3. Vito D, Geremia N, Fiore V, Princic E, Babudieri S, Madeddu G. Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia, Italy. Eur Rev Med Pharma- col Sci [Internet]. 2020 [cited 2021 Jan 22]; 24(14): 7861–8. Available from: https://www. europeanreview.org/article/22291. https://doi.org/10.26355/eurrev_202007_22291 PMID: 32744714

4. Vaira LA, Hopkins C, Salzano G, Petrocelli M, Melis A, Cucurullo M, et al. Olfactory and gustatory func- tion impairment in COVID-19 patients: Italian objective multicenter-study. Head & Neck [Internet]. 2020 May 21 [cited 2021 Jan 22]; 42(7). Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/hed. 26269. PMID: 32437022

5. Vaira LA, Deiana G, Fois AG, Pirina P, Madeddu G, De Vito A, et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases. Head and Neck [Internet]. 2020 Apr 27 [cited 2021 Jan 22]; 42(6). Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ hed.26204 PMID: 32342566

6. Geremia N, De Vito A, Gunnella S, Fiore V, Princic E, Panu C, et al. A Case of Vasculities-Like Skin Eruption Associated With COVID-19. Infectious Diseases in Clinical Practice [Internet]. 2020 Nov [cited 2021 Jan 22]; 28(6):e30–1. Available from: https://journals.lww.com/infectdis/Abstract/2020/11000/A_ Case_of_Vasculitis_Like_Skin_Eruption_Associated.22.aspx.

7. Guarneri C, Rullo EV, Pavone P, Berretta M, Ceccarelli M, Natale A, et al. Silent COVID-19: what your skin can reveal. Infectious Diseases [Internet]. 2021 Jan 01 [cited 2021 Jan 22]; 21(1):24–5. Available from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30402-3/fulltext. https://doi. org/10.1016/S1473-3099(20)30402-3 PMID: 32437697

8. Sant’Ana G, Imoto AM, Amorim FF, Taminato M, Peccin MS, Santana LA, et al. Infection and death in healthcare workers due to COVID-19: a systematic review. Acta Paul Enferm [Internet]. 2020 [cited 2020 Nov 6]; 33. Available from: https://www.scielo.br/scielo.php?pid= S010321002020000100601&script=sci_arttext&tlng=en.

9. COVID-19 has infected some 570,000 health workers and killed 2,500 in the Americas, PAHO Director says—PAHO/WHO. [Internet]. Pan American Health Organization; c2020- [cited 2020 Nov 6]. Available from: http://www.paho.org/en/news/2-9-2020-covid-19-has-infected-some-570000-health-workers- and-killed-2500-americas-paho.

10. Ağalar C, Engin DO ̈ . Protective measures for COVID-19 for healthcare providers and laboratory per- sonnel. Turk J Med Sci [Internt]. 2020 Apr 21 [cited 2020 Nov 6]; 50(SI-1):578–84. Available from: https://www.nlm.nih.gov/bsd/uniform_requirements.html. https://doi.org/10.3906/sag-2004-132 PMID: 32299205

11. Coronavirus Disease 2019 (COVID-19) [Internet]. Centers for Disease Control and Prevention; c2020- [cited 2020 Nov 6]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control. html.

12. Coronavirus disease (covid-19) outbreak: rights, roles and responsibilities of health workers, including key considerations for occupational safety and health: Interim guidance. [Internet]. World Health Orga- nization; c2020- [cited 2020 Nov 6]. Available from: https://www.who.int/docs/default-source/ coronaviruse/who-rights-roles-respon-hw-covid-19.pdf?sfvrsn=bcabd401_0.

13. Galvis V, Spinelli FR, Tello A, Sossa CL, Higuera JD, Go ́ mez ED, et al. Hydroxychloroquine as prophy- laxis for coronavirus SARS-CoV-2 infection: review of the ongoing clinical trials. Arch Bronconeumol

PLOS ONE | https://doi.org/10.1371/journal.pone.0247163 February 16, 2021 10 / 12

PLOS ONE

Role of oral ivermectin chemoprophylaxis in control of SARS-CoV-2 infection

14.

15.

16.

17.

18.

19.

20. 21.

22.

23.

24.

25.

26.

27.

28.

29.

[Internet]. 2020 [cited 2020 Nov 6]; 56(9):606–8. Available from: https://europepmc.org/article/med/ 32571633. https://doi.org/10.1016/j.arbres.2020.05.008 PMID: 32571633

Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis for SARS-CoV-2 infection (in suppression of previous advisory date 23rd March, 2020) [Internet]. Ministry of Health and Family Wel- fare; c2020- [cited 2020 Nov 6]. Available from: https://www.mohfw.gov.in/pdf/ RevisedadvisoryontheuseofhydroxychloroquineasprophylaxisforSARSCOVID19infection.pdf.

Coronavirus disease (COVID-19): Hydroxychloroquine [Internet]. World Health Organisation; c2020- [cited 2020 Nov 6]. Available from: https://www.who.int/news-room/q-a-detail/coronavirus-disease- covid-19-hydroxychloroquine.

Mahmud DR. A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care. clinicaltrials.gov Report No.: results/NCT04523831. [Internet]. 2020 Oct [cited 2020 Nov 4]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT04523831.

Shouman W. Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19. clinicaltrials.gov Report No.: NCT04422561 [Internet]. 2020 Aug [cited 2020 Nov 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT04422561.

Aguirre Chang G, Trujillo Figueredo A. COVID-19: ivermectin prophylaxis in adult contacts. First Report on Health Personnel and Post-Exposure Prophylaxis. Research Gate [Internet]. 2020 Jul 21 [cited 2020 Nov 6] Available from: https://www.researchgate.net/publication/344251319_COVID-19_ivermectin_ prophylaxis_in_adult_contacts_First_Report_on_Health_Personnel_and_Post-Exposure_Prophylaxis.

Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter J-J. Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study). Chest [Internet]. 2020 Oct 13 [cited 2020 Nov 6]; 159(1):85–92. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC7550891/. https://doi.org/10.1016/j.chest.2020.10.009 PMID: 33065103

nMaster. Version2.0—Sample Size Software. [Software]. Department of Biostatistics, CMC, Vellore [cited 2020 Nov 6]. Available from: http://www.cmc-biostatistics.ac.in/nmaster/.

Health workers exposure risk assessment and management in the context of COVID-19 virus: interim guidance [Internet]. World Health Organization; c2020 Mar 4- [cited 2020 Nov 6]. Available from: https:// apps.who.int/iris/handle/10665/331340.

Ministry of Health and Family Welfare, Government of India. Advisory on the use of Hydroxychloroquine as prophylaxis for SARS-CoV-2 Infection. [Internet] 2020 [cited 2021 Jan 20]. Available from: https:// http://www.mohfw.gov.in/pdf/ AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection. pdf.

Qian M, Jiang J. COVID-19 and social distancing. Z Gesundh Wiss [Internet]. 2020 May 25 [cited 2020 Nov 6];1–3. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247774/. https://doi.org/ 10.1007/s10389-020-01321-z PMID: 32837835

Galvin CJ, Li Y-CJ, Malwade S, Syed-Abdul S. COVID-19 preventive measures showing an unintended decline in infectious diseases in Taiwan. Int J Infect Dis. [Internet].2020 [cited 2020 Nov 6]; 98:18–20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247774/. https://doi.org/10.1016/j.ijid. 2020.06.062 PMID: 32585283

Teslya A, Pham TM, Godijk NG, Kretzschmar ME, Bootsma MC, Rozhnova G. Impact of self-imposed prevention measures and short-term government intervention on mitigating and delaying a COVID-19 epidemic: A modelling study. PLOS Medicine [Internet]. 2020 [cited 2020 Nov 6]; 17(12): e1003499. Available from: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003166. PMID: 33275595

Lahiri A, Jha SS, Bhattacharya S, Ray S, Chakraborty A. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context. Indian J Public Health [Internet]. 2020 [cited 2020 Nov 6]; 64(6):156. Available from: https://www.ijph.in/article.asp?issn= 0019-557X;year=2020;volume=64;issue=6;spage=156;epage=167;aulast=Lahiri. https://doi.org/10. 4103/ijph.IJPH_464_20 PMID: 32496248

Wang X, Pasco RF, Du Z, Petty M, Fox SJ, Galvani AP, et al. Impact of social distancing measures on coronavirus disease healthcare demand, central Texas, USA. Emerg Infect Dis [Internet]. 2020 [cited 2020 Nov 6]; 26(10):2361. Available from: https://wwwnc.cdc.gov/eid/article/26/10/20-1702_article. https://doi.org/10.3201/eid2610.201702 PMID: 32692648

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res [Internet]. 2020 [cited 2020 Nov 6];104787. Available from: https://www.sciencedirect.com/science/article/pii/S0166354220302011. https://doi.org/10.1016/j. antiviral.2020.104787 PMID: 32251768

Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med [Internet]. 2020 Aug 6

PLOS ONE | https://doi.org/10.1371/journal.pone.0247163 February 16, 2021 11 / 12

PLOS ONE

Role of oral ivermectin chemoprophylaxis in control of SARS-CoV-2 infection

30.

31.

32.

[cited 202 Nov 6]; 383(6):517–25. Available from: https://pubmed.ncbi.nlm.nih.gov/32492293/. https:// doi.org/10.1056/NEJMoa2016638 PMID: 32492293

Colunga Biancatelli RML, Berrill M, Catravas JD, Marik PE. Quercetin and vitamin C: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19). Front Immunol [Internet]. 2020 Jun 19 [cited 2020 Nov 6]; 11:1451. Available from: https://www.ncbi.nlm.nih. gov/pmc/articles/PMC7318306/. https://doi.org/10.3389/fimmu.2020.01451 PMID: 32636851

Cheng RZ, Kogan M, Davis D. Ascorbate as Prophylaxis and Therapy for COVID-19—Update From Shanghai and US Medical Institutions. Glob Adv Health Med [Internet]. 2020 [cited 2020 Nov 6]; 9:2164956120934768. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372609/. https://doi.org/10.1177/2164956120934768 PMID: 32733775

Feyaerts AF, Luyten W. Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19? Nutrition [Internet]. 2020 Jul 25 [cited 2020 Nov 6]; 79:110948. Available from: https://www.ncbi.nlm. nih.gov/pmc/articles/PMC7381407/. https://doi.org/10.1016/j.nut.2020.110948 PMID: 32911430

PLOS ONE | https://doi.org/10.1371/journal.pone.0247163 February 16, 2021 12 / 12